Product logins

Find logins to all Clarivate products below.


Biosimilars | Target Product Profile Simulator | Oncology | 2020

Related Market Assessment Reports

Report
Biosimilars – Current Treatment – Immunology
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Respiratory
In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…
Report
Biosimilars – Forecast – Endocrinology
In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3…